TRIAMCINOLONE Drug Patent Profile
✉ Email this page to a colleague
When do Triamcinolone patents expire, and when can generic versions of Triamcinolone launch?
Triamcinolone is a drug marketed by Barr, Impax Labs, Ivax Sub Teva Pharms, Mylan, Purepac Pharm, Roxane, Sandoz, Teva, Watson Labs, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Taro, Topiderm, Amneal, Eugia Pharma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Teva Pharms Usa, Epic Pharma Llc, Pai Holdings Pharm, Quagen, Wockhardt Bio Ag, Aurobindo Pharma Ltd, Cintex Svcs, Glenmark Pharms, Padagis Israel, Akorn, Lyne, Apotex, Perrigo Pharma Intl, and Rising. and is included in one hundred and fourteen NDAs.
The generic ingredient in TRIAMCINOLONE is triamcinolone diacetate. There are fifty-one drug master file entries for this compound. Additional details are available on the triamcinolone diacetate profile page.
Summary for TRIAMCINOLONE
US Patents: | 0 |
Applicants: | 46 |
NDAs: | 114 |
Raw Ingredient (Bulk) Api Vendors: | 76 |
Clinical Trials: | 397 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TRIAMCINOLONE |
Drug Sales Revenues: | Drug sales revenues for TRIAMCINOLONE |
DailyMed Link: | TRIAMCINOLONE at DailyMed |
Recent Clinical Trials for TRIAMCINOLONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Centre hospitalier de l'Université de Montréal (CHUM) | N/A |
Gadjah Mada University | Phase 1/Phase 2 |
Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal | Phase 4 |
Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE
Anatomical Therapeutic Chemical (ATC) Classes for TRIAMCINOLONE
US Patents and Regulatory Information for TRIAMCINOLONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | INJECTABLE;INJECTION | 209852-001 | Oct 5, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Fougera Pharms | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | OINTMENT;TOPICAL | 085691-003 | Approved Prior to Jan 1, 1982 | AT | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Morton Grove | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 088095-001 | Sep 1, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |